← feed

Is NCT02205398 results overdue?

Yes — results are overdue. Primary completion was 2017-01-20; the FDAAA-801 reporting deadline (2018-01-20) passed 3074 days ago and no results are posted on ClinicalTrials.gov.

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

NCT IDNCT02205398 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2017-01-20 (ACTUAL)
Reporting deadline2018-01-20 (completion + 365d)
Days overdue3074
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 71bb51691382ca77… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02205398. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →